The global Hodgkin lymphoma treatment market is expected to grow at a CAGR of 5.5% during the forecast period, from 2021 to 2030. The market is driven by factors such as increasing incidence of Hodgkin lymphoma and rising awareness about the disease. The North American region is expected to dominate the global market with a share of over 40%. This can be attributed to high prevalence rates in this region and increasing number of patients diagnosed with Hodgkin lymphoma in this region. -There are many clinical trials for Hodgkin lymphoma treatment that are ongoing or planned to start soon.
Industry Growth Insights published a new data on “Hodgkin Lymphoma Treatment Market”. The research report is titled “Hodgkin Lymphoma Treatment Market research by Types (Alocrest, ANK Program, Azacitidine, BMS-986016, BPX-501, Others), By Applications (Hospital, Clinic, Research Center), By Players/Companies Cell Medica Limited, Cellular Biomedicine Group, Inc., Constellation Pharmaceuticals, Inc., Curis, Inc., Faron Pharmaceuticals Oy, Fate Therapeutics, Inc., Gamida Cell Ltd., Gilead Sciences, Inc., Incyte Corporation, Merck & Co., Inc., Mirati Therapeutics Inc., Molecular Templates Inc., NantKwest, Inc.”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Hodgkin Lymphoma Treatment Market Research Report
By Type
Alocrest, ANK Program, Azacitidine, BMS-986016, BPX-501, Others
By Application
Hospital, Clinic, Research Center
By Companies
Cell Medica Limited, Cellular Biomedicine Group, Inc., Constellation Pharmaceuticals, Inc., Curis, Inc., Faron Pharmaceuticals Oy, Fate Therapeutics, Inc., Gamida Cell Ltd., Gilead Sciences, Inc., Incyte Corporation, Merck & Co., Inc., Mirati Therapeutics Inc., Molecular Templates Inc., NantKwest, Inc.
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
243
Number of Tables & Figures
171
Customization Available
Yes, the report can be customized as per your need.
Global Hodgkin Lymphoma Treatment Market Report Segments:
The global Hodgkin Lymphoma Treatment market is segmented on the basis of:
Types
Alocrest, ANK Program, Azacitidine, BMS-986016, BPX-501, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, Research Center
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Cell Medica Limited
- Cellular Biomedicine Group, Inc.
- Constellation Pharmaceuticals, Inc.
- Curis, Inc.
- Faron Pharmaceuticals Oy
- Fate Therapeutics, Inc.
- Gamida Cell Ltd.
- Gilead Sciences, Inc.
- Incyte Corporation
- Merck & Co., Inc.
- Mirati Therapeutics Inc.
- Molecular Templates Inc.
- NantKwest, Inc.
Highlights of The Hodgkin Lymphoma Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Alocrest
- ANK Program
- Azacitidine
- BMS-986016
- BPX-501
- Others
- By Application:
- Hospital
- Clinic
- Research Center
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Hodgkin Lymphoma Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Hodgkin lymphoma is a type of cancer that starts in the lymph nodes. Treatment usually includes chemotherapy and radiation therapy.
Some of the key players operating in the hodgkin lymphoma treatment market are Cell Medica Limited, Cellular Biomedicine Group, Inc., Constellation Pharmaceuticals, Inc., Curis, Inc., Faron Pharmaceuticals Oy, Fate Therapeutics, Inc., Gamida Cell Ltd., Gilead Sciences, Inc., Incyte Corporation, Merck & Co., Inc., Mirati Therapeutics Inc., Molecular Templates Inc., NantKwest, Inc..
The hodgkin lymphoma treatment market is expected to grow at a compound annual growth rate of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Hodgkin Lymphoma Treatment Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Hodgkin Lymphoma Treatment Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Hodgkin Lymphoma Treatment Market - Supply Chain
4.5. Global Hodgkin Lymphoma Treatment Market Forecast
4.5.1. Hodgkin Lymphoma Treatment Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Hodgkin Lymphoma Treatment Market Size (000 Units) and Y-o-Y Growth
4.5.3. Hodgkin Lymphoma Treatment Market Absolute $ Opportunity
5. Global Hodgkin Lymphoma Treatment Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Hodgkin Lymphoma Treatment Market Size and Volume Forecast by Type
5.3.1. Alocrest
5.3.2. ANK Program
5.3.3. Azacitidine
5.3.4. BMS-986016
5.3.5. BPX-501
5.3.6. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Hodgkin Lymphoma Treatment Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Hodgkin Lymphoma Treatment Market Size and Volume Forecast by Application
6.3.1. Hospital
6.3.2. Clinic
6.3.3. Research Center
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Hodgkin Lymphoma Treatment Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Hodgkin Lymphoma Treatment Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Hodgkin Lymphoma Treatment Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Hodgkin Lymphoma Treatment Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Hodgkin Lymphoma Treatment Demand Share Forecast, 2019-2026
9. North America Hodgkin Lymphoma Treatment Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Hodgkin Lymphoma Treatment Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Hodgkin Lymphoma Treatment Market Size and Volume Forecast by Application
9.4.1. Hospital
9.4.2. Clinic
9.4.3. Research Center
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Hodgkin Lymphoma Treatment Market Size and Volume Forecast by Type
9.7.1. Alocrest
9.7.2. ANK Program
9.7.3. Azacitidine
9.7.4. BMS-986016
9.7.5. BPX-501
9.7.6. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Hodgkin Lymphoma Treatment Demand Share Forecast, 2019-2026
10. Latin America Hodgkin Lymphoma Treatment Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Hodgkin Lymphoma Treatment Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Hodgkin Lymphoma Treatment Market Size and Volume Forecast by Application
10.4.1. Hospital
10.4.2. Clinic
10.4.3. Research Center
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Hodgkin Lymphoma Treatment Market Size and Volume Forecast by Type
10.7.1. Alocrest
10.7.2. ANK Program
10.7.3. Azacitidine
10.7.4. BMS-986016
10.7.5. BPX-501
10.7.6. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Hodgkin Lymphoma Treatment Demand Share Forecast, 2019-2026
11. Europe Hodgkin Lymphoma Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Hodgkin Lymphoma Treatment Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Hodgkin Lymphoma Treatment Market Size and Volume Forecast by Application
11.4.1. Hospital
11.4.2. Clinic
11.4.3. Research Center
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Hodgkin Lymphoma Treatment Market Size and Volume Forecast by Type
11.7.1. Alocrest
11.7.2. ANK Program
11.7.3. Azacitidine
11.7.4. BMS-986016
11.7.5. BPX-501
11.7.6. Others
11.8. Basis Point Share (BPS) Analysis byType
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Hodgkin Lymphoma Treatment Demand Share, 2019-2026
12. Asia Pacific Hodgkin Lymphoma Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Hodgkin Lymphoma Treatment Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Hodgkin Lymphoma Treatment Market Size and Volume Forecast by Application
12.4.1. Hospital
12.4.2. Clinic
12.4.3. Research Center
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Hodgkin Lymphoma Treatment Market Size and Volume Forecast by Type
12.7.1. Alocrest
12.7.2. ANK Program
12.7.3. Azacitidine
12.7.4. BMS-986016
12.7.5. BPX-501
12.7.6. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Hodgkin Lymphoma Treatment Demand Share, 2019-2026
13. Middle East & Africa Hodgkin Lymphoma Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Hodgkin Lymphoma Treatment Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Hodgkin Lymphoma Treatment Market Size and Volume Forecast by Application
13.4.1. Hospital
13.4.2. Clinic
13.4.3. Research Center
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Hodgkin Lymphoma Treatment Market Size and Volume Forecast by Type
13.7.1. Alocrest
13.7.2. ANK Program
13.7.3. Azacitidine
13.7.4. BMS-986016
13.7.5. BPX-501
13.7.6. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Hodgkin Lymphoma Treatment Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Hodgkin Lymphoma Treatment Market: Market Share Analysis
14.2. Hodgkin Lymphoma Treatment Distributors and Customers
14.3. Hodgkin Lymphoma Treatment Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Cell Medica Limited
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Cellular Biomedicine Group, Inc.
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Constellation Pharmaceuticals, Inc.
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Curis, Inc.
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Faron Pharmaceuticals Oy
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Fate Therapeutics, Inc.
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Gamida Cell Ltd.
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Gilead Sciences, Inc.
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Incyte Corporation
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Merck & Co., Inc.
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Mirati Therapeutics Inc.
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Molecular Templates Inc.
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. NantKwest, Inc.
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook